Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes

2014-08-27 03:43:37 | BioPortfolio


The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and dyslipidemia.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Dyslipidemia/Glucose Metabolism Disorder


fenofibrate and metformin combination (drug)


Site 201




Solvay Pharmaceuticals

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:43:37-0400

Clinical Trials [3512 Associated Clinical Trials listed on BioPortfolio]

Acceptability of a Fixed Combination of Fenofibrate and Metformin

The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia...

Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO

To demonstrate in patients with T2DM and dyslipidemia not appropriately controlled with a statin and receiving metformin, the superiority of a fixed combination of fenofibrate and metformi...

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

Patients with metabolic syndrome, insulin resistance, and elevated triglycerides of 150 mg/dl or higher will be randomized to one of four groups: 1) placebo; 2) metformin; 3) fenofibrate; ...

Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI

Under conditions of first-line drug treatment in antidiabetic drug naïve/drug free patients with type 2 diabetes mellitus and dyslipidemia, to show that :- the efficacy of a fixed combina...

A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.

The purpose of this study was to study the effect of different combinations of fenofibrate and metformin on the cluster of metabolic syndrome (MetS) biochemical abnormalities, and to deter...

PubMed Articles [18163 Associated PubMed Articles listed on BioPortfolio]

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.

Patients with diabetes type 2 have an increased risk for cardiovascular disease and commonly use combination therapy consisting of the anti-diabetic drug metformin and a cholesterol-lowering statin. H...

Rifampicin alters metformin plasma exposure but not blood glucose levels in diabetic tuberculosis patients.

The pharmacokinetic and clinical implications of combining metformin with rifampicin are relevant to increasing numbers of diabetic tuberculosis (TB) patients across the world and are yet unclear. We ...

Bidirectional regulation of adenosine 5'-monophosphate-activated protein kinase activity by berberine and metformin in response to changes in ambient glucose concentration.

Both berberine and metformin are well-known antihyperglycemic agents for diabetes treatment. Adenosine monophosphate (AMP)-activated protein kinase (AMPK) activation is often considered as the most im...

Patterns of altered regional brain glucose metabolism in borderline personality disorder and bipolar II disorder.

The relationship between borderline personality disorder (BPD) and bipolar II disorder (BIP-II) is disputed but understudied. Here, we investigated brain glucose metabolism in these patient groups and...

A Gut Feeling for Metformin.

Metformin is a first-line glucose-lowering agent in patients with type 2 diabetes (T2D). Recently in Nature Medicine, Sun et al. (2018) reported that short-term metformin therapy decreases gut Bacter...

Medical and Biotech [MESH] Definitions

A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES.

A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)

Maintenance of a constant blood glucose level by perfusion or infusion with glucose or insulin. It is used for the study of metabolic rates (e.g., in glucose, lipid, amino acid metabolism) at constant glucose concentration.

Peptide hormones that cause an increase in the absorption of GLUCOSE by cells within organs such as LIVER, MUSCLE and ADIPOSE TISSUE. During normal metabolism insulins are produced by the PANCREATIC BETA CELLS in response to increased GLUCOSE. Natural and chemically-modified forms of insulin are also used in the treatment of GLUCOSE METABOLISM DISORDERS such as DIABETES MELLITUS.

An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells. It is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6-phosphate. (Stedman, 26th ed)

More From BioPortfolio on "Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes"

Quick Search


Relevant Topic

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Searches Linking to this Trial